This House resolution supports designating June 1 through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week." The text says hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that affects about 3,300,000 people in the United States. It describes common symptoms (painful nodules, abscesses, tunnels under the skin, and scarring) and lists five main areas of suffering: pain, drainage, odor, itching, and psychological distress. The resolution notes a high completed suicide rate among people with HS (second only to melanoma), that 75 percent of people with HS are misdiagnosed or diagnosed after age 25, and that three biologic therapies are FDA approved for HS. The resolution expresses support for increasing awareness and education, improving timely and accurate diagnosis, supporting biomedical research, accelerating development and access to treatments, and advancing policies to improve care and quality of life. The resolution was introduced in the House and referred to the Committee on Energy and Commerce.
The resolution expresses the House's support for an awareness week and recognizes priorities for HS care and research. The text calls for more awareness, better screening and culturally competent care, more research, faster development and broader access to treatments, and policies to improve care and quality of life for people with HS and their caregivers. The resolution itself does not include funding amounts or create specific new programs.
No publicly available information.
Supporters say an awareness week would increase public and clinician understanding, help catch HS earlier, reduce delayed diagnosis, encourage more research into causes and treatments, speed development of effective therapies, and promote access to existing treatments, wound care, and comprehensive care.
No publicly available information.